CN1110313C - A set of medicine for prevention and curing of cholesthiasis disease and plan for discriminating choleithiasis kind - Google Patents

A set of medicine for prevention and curing of cholesthiasis disease and plan for discriminating choleithiasis kind Download PDF

Info

Publication number
CN1110313C
CN1110313C CN98104574A CN98104574A CN1110313C CN 1110313 C CN1110313 C CN 1110313C CN 98104574 A CN98104574 A CN 98104574A CN 98104574 A CN98104574 A CN 98104574A CN 1110313 C CN1110313 C CN 1110313C
Authority
CN
China
Prior art keywords
medicine
cholelithiasis
parts
calculus
applicable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN98104574A
Other languages
Chinese (zh)
Other versions
CN1228969A (en
Inventor
许秋菊
张毅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN98104574A priority Critical patent/CN1110313C/en
Publication of CN1228969A publication Critical patent/CN1228969A/en
Application granted granted Critical
Publication of CN1110313C publication Critical patent/CN1110313C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a set of medicine for preventing and curing biliary tract diseases of chronic cholecystitis, intra-and extrahepatic bile duct calculus, cholecystolithiasis, biliary postoperative residual calculus, gallbladder-heart syndrome, etc. The medicine has different megascopic calculus dissolving functions to more than 90% of biliary calculus, and has broad-spectrum calculus dissolving and preventing function and the ratio of curative effect and price which are obviously superior to those of the known medicine until now. The present invention has the new purpose of calculus kind identification so that the abuses of calculus forming acceleration, etc. caused by blind medication by patients are avoided. The present invention is novel special calculus dissolving and preventing medicine which combines the three methods of dissolution, removal and prevention into a whole.

Description

A kind of medicine of preventing and treating cholelithiasis
We apply for one group of medicine and application that prevents and treats cholelithiasis to State Patent Office the present, and purpose is to make this part invention achievement obtain complete patent protection comprehensively.
Show at present according to statistics both at home and abroad, after liver and bile stone disease (abbreviation cholelithiasis) patient implements lithotomy, in 3 years the recurrence of hepatolithiasis rate up to 30%~50%, after 5 years then up to more than 60%.And we find when 365 routine cholelithiasiss recurrence patients are followed up a case by regular visits to, the patient 64% or more since the postoperative selection prevent that the stone medicine is improper and cause.Trace it to its cause, mainly be because clinicist and patient can not correctly discern choleithiasis kind, and existing market is sold the medicine of control cholelithiasis, what have has only the anti-inflammatory and choleretic effect, what have can only the dissolving cholesterol calculus, and exist side effect many, cost an arm and a leg, make defectives such as most of patients is difficult to bear.Event is clinical to be difficult to accomplish rational use of drug, thereby is seriously restricting clinical molten anti-stone curative effect.This pharmaceutical composition just is being based on the above-mentioned difficult problem of solution and is inventing.It had both had the molten anti-masonry usefulness of significant wide spectrum, had possessed the new purposes of differentiating choleithiasis kind simultaneously again, had avoided quickening many drawbacks such as cholelithiasis formation on the contrary because of the blindness medication.
Specifically, the present invention relates to the medicine of one group of treatment and biliary tract diseases such as prevention chronic cholecystitis, liver inside and outside bile duct stone, cholelithiasis, biliary postoperative residual calculus and gallbladder heart syndrome.Its prescription derives from traditional Chinese medical science secret recipe, again by clinical verification for many years, carries out the science screening in conjunction with modern pharmacology and forms.It meets rules such as traditional Chinese medical science depressed liver-energy dispersing and function of gallbladder promoting, clearing away heat-damp and promoting diuresis, nourishing yin and activating blood, hard masses softening and resolving, makes catharsis functional rehabilitation, bile secretion and the drainage of liver normal, thereby plays the effect of lithodialysis, calculus, anti-stone.Its component and proportion relation are preferably: 1~10 part of unsaturated fatty acid, 0.004~0.15 part of antioxidant, phosphatidase 10 .05~3 part, natural glue or 1~50 part of medicinal resin, 1~25 part of Endothelium corneum, 1~30 part of Pericarpium Citri Reticulatae, 1~35 part on Pericarpium Citri Reticulatae Viride, 1~50 part of Radix Scutellariae, 1~30 part of Rhizoma Coptidis; Be preferably: 1.5~8 parts of unsaturated fatty acids, 0.005~0.1 part of antioxidant, phosphatidase 10 .1~2.5 part, 2~40 parts of natural glue or medicinal resins, 4~20 parts of Endothelium corneum, 0.1~3 part of 2~25 parts of Pericarpium Citri Reticulataes or hesperidin, 0.2~3 part of 2~30 parts on Pericarpium Citri Reticulatae Viride or limonene, 0.2~5 part of 3~40 parts of Radix Scutellariaes or baicalin or baicaligenin, 0.1~5 part of 2~25 parts of Rhizoma Coptidis or berberine, add a small amount of synergist, through sterilization, modern crafts such as pulverizing and extraction are refining to form, but also unsaturated fatty acid and derivant thereof can contained, on the bases such as antioxidant, select suitable medicine and proportioning according to different types of cholelithiasis.
More detailed saying, the unsaturated fatty acid of indication comprises in the component: consistent lubricant acid, oleic acid, linoleic acid, linolenic acid, arachidonic acid, linoleic acid, EPA (eicosapentaenoic acid) and DHA (docosahexenoic acid) or the like are first-selection with linoleic acid and derivant thereof wherein.Antioxidant can be selected vitamin E and Natural antioxidant pycnogenol for use.Phospholipid will be handled through the past sterin.In common knowledge as everybody, phospholipid had both belonged to unsaturated fatty acid, belonged to the oiliness antioxidant again.Natural glue can utilize natural drug such as Carapax Trionycis to make, and selects medicinal resin or resin bead to replace natural glue that better curative effect is also arranged certainly.Endothelium corneum is chicken, duck, Endothelium corneum Anseris domestica, wherein is first-selected with the Endothelium corneum Anseris domestica.From natural drugs such as Pericarpium Citri Reticulatae, Pericarpium Citri Reticulatae Viride, Radix Scutellariae, Rhizoma Coptidis, can extract plurality of active ingredients, as hesperidin, limonene, baicalin or baicaligenin, berberine etc.The synergist master who is said in the prescription refers to nicotinic acid, inositol, vitamin C, vitamin B6 etc.
In addition, we find in experiment, said composition can significantly increase the excretion of bile mesobilirubin, and the combining of bilirubin and said composition, played solubilising cholelithiasis effect in the unexpected body, this may be that bilirubin has been brought into play especially effectively antioxidation, has stably prevented the loss prematurely in vivo of linoleic acid and other unsaturated fatty acid, thereby the ability of its transformed cholesterol is significantly strengthened.The characteristic of the anti-stone of the beat all calculus dissolving and excreting that said composition had also shows its summation that is higher than in the compositions the independent or curative effect of addition of every kind of composition own evident in efficacy, has played separately or the molten anti-masonry usefulness of wide spectrum that addition itself is not had.
We carry out the experiment of external lithodialysis to 240 routine cholelithiasiss at random, and the result shows, said composition has in various degree naked eyes observability litholytic effect to the cholelithiasis more than 90%.We get the postoperative patient of stone by the cholelithiasis and the 544 routine percutaneous gallbladder mirrors that 852 examples are met Chinese bureau of drug administration new drug (Chinese medicine) in 1989 clinical research guideline, adopt continuously or be interrupted and alternately take 1~4 course of treatment of said composition (the per half a year course of treatment), carry out clinical verification, confirm through the front and back ultrasound diagnosis, treatment cholelithiasis and chronic cholecystitis total effective rate are respectively 93.7% and 96%, treatment gallbladder heart syndrome total effective rate is 92.4%, the recurrence of prevention liver and bile stone, the recurrence of hepatolithiasis rate is controlled in 10% in 5 years.Its curative effect all is higher than medicine matched groups such as taking XIAOYAN LIDAN PIAN, DANTONG, and the zoopery result is similar to clinical verification.The molten anti-masonry of the wide spectrum that this pharmaceutical composition had is used and curative effect price ratio in sum, significantly is better than known drug so far.
Differentiate the choleithiasis kind technical scheme, its technical characterictic comprises step and environmental condition.Its key step comprises: it is an amount of to get the cholelithiasis solvent, and cholelithiasis is put into solvent, is advisable so that cholelithiasis is soaked fully.Leave standstill or jolting every day solvent (or boiling) 10 hours in, ambient temperature is controlled between-5 ℃ to 150 ℃, pressure is controlled at-1KPa to 15KPa between.According to the color of cholelithiasis with whether dissolve or cracking, and the time that dissolving or cracking took place, illustrate molten anti-masonry with and differentiate choleithiasis kind.Its material property is: the cholelithiasis solvent.
This pharmaceutical composition collected in the small container (also can directly select the cholelithiasis solvent for use), placed one day, it is an amount of to get its clarification medicinal liquid, again cholelithiasis is put into medicinal liquid, is advisable so that cholelithiasis is soaked fully.Every day shake the medicinal liquid 3~30 minutes that cholelithiasis is housed, in medicinal liquid, do not stop to roll to be advisable with cholelithiasis thereafter.Environmental condition is: temperature-5 ℃~150 ℃, pressure-1KPa~15KPa.The program of differentiating cholelithiasis is as follows: the cholelithiasis outward appearance be white to light lark, as above interior cholelithiasis has and dissolution phenomena such as dwindles 1 week of scheme, is cholesterol and Combination cholelithiasis thereof; The cholelithiasis outward appearance is faint yellow to brownish black, and cholelithiasis has the cracking phenomenon in 5 days, is bilirubin and Combination cholelithiasis thereof; The cholelithiasis outward appearance is white to brownish black, and no cholelithiasis dissolves or the cracking phenomenon in 1 week, and being calcic is main Combination cholelithiasis.Such scheme also can be by changing cholelithiasis solvent and environmental condition such as temperature and pressure, leave standstill or prolong the time of at every turn shaking solvent, reduce or increase the intensity of shaking solvent, the time that Mi Yanchang or shortening lithodialysis phenomenon are taken place, can differentiate choleithiasis kind equally with this.
Embodiment:
(example one) following medicine is formed and proportion relation mainly is applicable to control cholesterol and Combination cholelithiasis thereof, but also is applicable to other kind cholelithiasis: linoleic acid 10g, vitamin E 0.05g, phosphatidase 10 .7g, natural glue 40g, Endothelium corneum 10g, hesperidin 0.3g, limonene 1g, berberine 0.2g.
(example two) following medicine is formed and proportion relation mainly is applicable to control bilirubin and Combination cholelithiasis thereof, also is applicable to other kind cholelithiasis: Ethyl linoleate 9g, vitamin E 0.06g, natural glue 20g, Endothelium corneum 20g, hesperidin 0.2g, baicalin 4g, berberine 4g nicotinic acid 0.75g, vitamin B6 0.15g.
(example three) following medicine is formed and proportion relation is applicable to that mainly the control calcic is main Combination cholelithiasis, also is applicable to other kind cholelithiasis: linoleic acid 10g, vitamin E 0.1g, phosphatidase 12 g, medicinal resin or natural glue 10g, hesperidin 2.5g, limonene 0.4g, baicalin or baicaligenin 1.5g, berberine 1g, vitamin B6 0.06g.
But also can contain on unsaturated fatty acid and the bases such as derivant, antioxidant thereof, select suitable medicine and proportioning according to different types of cholelithiasis.

Claims (6)

1. medicine of preventing and treating cholelithiasis, it is characterized in that it can be on the basis of containing unsaturated fatty acid and derivant thereof, antioxidant, select suitable raw material and proportioning according to different types of cholelithiasis, it is made by the following weight proportion raw material: 1~10 part of unsaturated fatty acid, 0.004~0.15 part of antioxidant, phosphatidase 10 .05~3 part, 1~50 part of natural glue, 1~25 part of Endothelium corneum, 1~30 part of Pericarpium Citri Reticulatae, 1~35 part on Pericarpium Citri Reticulatae Viride, 1~50 part of Radix Scutellariae, 1~30 part of Rhizoma Coptidis.
2. the medicine of control cholelithiasis according to claim 1, wherein the weight proportion of each raw material is: 1.5~8 parts of unsaturated fatty acids, 0.005~0.1 part of antioxidant, phosphatidase 10 .1~2.5 part, 2~40 parts of natural glues, 4~20 parts of Endothelium corneum, 2~25 parts of Pericarpium Citri Reticulataes, 2~30 parts on Pericarpium Citri Reticulatae Viride, 3~40 parts of Radix Scutellariaes, 2~25 parts of Rhizoma Coptidis.
3. the medicine of control cholelithiasis according to claim 2, it is characterized in that: wherein 0.1~3 part of replacement of 2~25 parts of available hesperidins of Pericarpium Citri Reticulatae, 0.2~3 part of replacement of 2~30 parts of available limonenes of Pericarpium Citri Reticulatae Viride, 3~40 parts of available baicalins of Radix Scutellariae or 0.2~5 part of replacement of baicaligenin, 0.1~5 part of replacement of 2~25 parts of available berberine of Rhizoma Coptidis.
4. one kind mainly is applicable to control cholesterol and Combination cholelithiasis thereof, but also be applicable to the medicine of other kind cholelithiasiss, it is characterized in that it is made up of the following weight proportion raw material: linoleic acid 10g, vitamin E 0.05g, phosphatidase 10 .7g, natural glue 40g, Endothelium corneum 10g, hesperidin 0.3g, limonene 1g, berberine 0.2g.
5. one kind mainly is applicable to control bilirubin and Combination cholelithiasis thereof, but also be applicable to the medicine of other kind cholelithiasiss, it is characterized in that forming: Ethyl linoleate 9g, vitamin E 0.06g, natural glue 20g, Endothelium corneum 20g, hesperidin 0.2g, baicalin 4g, berberine 4g, nicotinic acid 0.75g, vitamin B6 0.15g by the following weight proportion raw material.
6. one kind is applicable to that mainly the control calcic is main Combination cholelithiasis, but also be applicable to the medicine of other kind cholelithiasiss, it is characterized in that forming: linoleic acid 10g, vitamin E 0.1g, phosphatidase 12 g, natural glue 10g, hesperidin 2.5g, limonene 0.4g, baicaligenin 1.5g, berberine 1g, vitamin B6 0.06g by the following weight proportion raw material.
CN98104574A 1998-03-18 1998-03-18 A set of medicine for prevention and curing of cholesthiasis disease and plan for discriminating choleithiasis kind Expired - Fee Related CN1110313C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN98104574A CN1110313C (en) 1998-03-18 1998-03-18 A set of medicine for prevention and curing of cholesthiasis disease and plan for discriminating choleithiasis kind

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN98104574A CN1110313C (en) 1998-03-18 1998-03-18 A set of medicine for prevention and curing of cholesthiasis disease and plan for discriminating choleithiasis kind

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNB011251883A Division CN1184478C (en) 1998-03-18 1998-03-18 Gallstone kind identifying method and use

Publications (2)

Publication Number Publication Date
CN1228969A CN1228969A (en) 1999-09-22
CN1110313C true CN1110313C (en) 2003-06-04

Family

ID=5218301

Family Applications (1)

Application Number Title Priority Date Filing Date
CN98104574A Expired - Fee Related CN1110313C (en) 1998-03-18 1998-03-18 A set of medicine for prevention and curing of cholesthiasis disease and plan for discriminating choleithiasis kind

Country Status (1)

Country Link
CN (1) CN1110313C (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009060452A2 (en) * 2007-11-08 2009-05-14 Galmed International Ltd. Methods and compositions for treating biliary cholesterol crystallization and related conditions
CN102895462B (en) * 2012-09-27 2014-03-12 林一帆 Traditional Chinese medicine for preventing and treating gallstone relapse

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1127128A (en) * 1995-09-14 1996-07-24 隋嫣玲 Traditional Chinese medicine for cholelithiasis and preparing method

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1127128A (en) * 1995-09-14 1996-07-24 隋嫣玲 Traditional Chinese medicine for cholelithiasis and preparing method

Also Published As

Publication number Publication date
CN1228969A (en) 1999-09-22

Similar Documents

Publication Publication Date Title
KR100804480B1 (en) Memory enhancing composition
JP2002527389A (en) Combination of carnitine and resveratrol for prevention or treatment of cerebral and age-related diseases
KR102121153B1 (en) Dietary herbal composition, dietary herbal medicine pill comprising the same and method for manufacturing thereof
CN105920476B (en) Traditional Chinese medicine composition for preventing and treating Alzheimer's disease and preparation method thereof
WO2002074295A1 (en) A composition for the prophylaxis or treatment of senile dementia
EP1810678A1 (en) Use of morphine and naloxone for drug substitution
CN1110313C (en) A set of medicine for prevention and curing of cholesthiasis disease and plan for discriminating choleithiasis kind
JPH0725777A (en) Neurotrophic factor synthesis promoter
KR20060130148A (en) Use of ginkgo complexes to enhance cognitive function and reduce mental fatigue
KR101401628B1 (en) Tablet for improving hepatic function and method of manufacturing thereof
DE202008007923U1 (en) suppository
KR20170062781A (en) Composition Comprising Black Ginseng Extract having Improving Activity of Cognitive Function
CN1184478C (en) Gallstone kind identifying method and use
CN100518771C (en) Ointment for treating naevus and preparing method thereof
CN1899387B (en) Method for preventing and treating child convulsion and its preparing method
CN109966278B (en) Application of oxalylmalic acid in the preparation of drugs for the treatment of nerve cell injury
CN1173355A (en) Recovering liquid for oral cavity ulcer
CN1083716A (en) Sal ammoniac oculentum
KR20110004691A (en) Pharmaceutical composition and health food composition containing rhododendron extract having brain function improvement effect
CN105663193B (en) Rice washing water prepared pseudo-ginseng powder as well as preparation and preparation method thereof
CN1053810C (en) Compound capsule for fever release pain stop and anti-inflammation
CN104258034A (en) Traditional Chinese medicine composition for boosting immunity
CN1319562C (en) Disinfectant bactericidal Chinese medicine preparation and producing process thereof
CN1201769C (en) Medicine for treating diabetes, nephropathy
CN112076323B (en) Placebo and application thereof

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee